Lymphoma, B-Cell News

FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma - FDA.gov



TheStreet.com
 
FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma 
FDA.gov
The U.S. Food and Drug Administration today approved Yescarta (axicabtagene ciloleucel), a cell-based gene therapy, to treat adult patients with certain types of large B-cell lymphoma who have not responded to or who have relapsed after at least two ...
FDA Approves Gene Therapy to Treat Large B-Cell Lymphoma TheStreet.com
Gene Therapy Approved for B-Cell Lymphoma U.S. News & World Report
FDA approves Kite's Car T therapy Yescarta for B-Cell Lymphoma Pharmaceutical Business Review
CNN  -BioWorld Online  -OncLive  -gilead.com 
all 205 news articles » 


For Some, Cutting-Edge 'CAR-T' Treatment Unleashes 'Pac-Man' Cells Against Blood Cancer - WBUR



WBUR
 
For Some, Cutting-Edge 'CAR-T' Treatment Unleashes 'Pac-Man' Cells Against Blood Cancer 
WBUR
This week, the U.S. Food and Drug Administration approved the second therapy in this class, called Yescarta, to treat advanced B-cell lymphomas, like Wilkins'. The first CAR-T drug, Kymriah, received approval in August to treat an advanced form of ...
New treatment for cancer The Hindu
Coming soon at two Tampa Bay area hospitals: a cancer treatment that could replace chemo TBO.com
Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval Nasdaq
PMLiVE  -Medical Xpress 
all 22 news articles » 


FDA Approves Axi-Cel for Large B-cell Lymphoma - Targeted Oncology



FDA Approves Axi-Cel for Large B-cell Lymphoma 
Targeted Oncology
The CD19-directed CAR T-cell therapy axicabtagene ciloleucel (axi-cel; Yescarta) has been approved by the FDA for the treatment of adults with relapsed or ...
FDA Approves Axicabtagene Ciloleucel for Non-Hodgkin Lymphoma OncLive

all 2 news articles » 


The FDA approves Yescarta (axicabtagene ciloleucil) for treatment ... - Lymphoma Hub



Lymphoma Hub
 
The FDA approves Yescarta (axicabtagene ciloleucil) for treatment ... 
Lymphoma Hub
On 18th October 2017, the U.S. Food and Drug Administration (FDA) approved Kite Pharma's Yescarta (axicabtagene ciloleucil) for the treatment of relapsed or ...

and more » 


Researchers pinpoint genetic drivers of diffuse large B cell lymphoma - News-Medical.net



Researchers pinpoint genetic drivers of diffuse large B cell lymphoma 
News-Medical.net
Lymphoma is the most common blood cancer, but the diagnosis belies a wildly diverse and little understood genetic foundation for the disease that hampers ...

and more » 


Rosenberg: Yescarta is going to be lifesaving for patients with lymphomas - The Cancer Letter Publications



Rosenberg: Yescarta is going to be lifesaving for patients with lymphomas 
The Cancer Letter Publications
On Oct. 18, FDA approved Yescarta (axicabtagene ciloleucel) to treat adult patients with certain types of large B cell lymphoma who have not responded to or who have relapsed after at least two other kinds of treatment. The complete remission rate ...

 


FDA Approves Gilead Cancer Gene Therapy - HuffPost



FDA Approves Gilead Cancer Gene Therapy 
HuffPost
(Reuters) - U.S. regulators approved on Wednesday a new therapy for a type of lymphoma, which was developed by Gilead Science Inc's (GILD.O) Kite Pharma, marking the second approval for this potentially revolutionary approach to fighting cancer.

 


Doctors Say New Cancer Treatment Might Even Be Cure CBS ... - CBS New York



CBS New York
 
Doctors Say New Cancer Treatment Might Even Be Cure CBS ... 
CBS New York
NEW YORK (CBSNewYork) ? Doctors say a new treatment for Non-Hodgkin's lymphoma might even be a cure. The treatment uses a patient's own immune ...

and more » 


New assay may boost targeted treatment of non-Hodgkin lymphoma - Medical Xpress



Medical Xpress
 
New assay may boost targeted treatment of non-Hodgkin lymphoma 
Medical Xpress
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer and the most frequently diagnosed non-Hodgkin lymphoma worldwide (nearly 40% of cases).

and more » 


Partnership to Develop Personalized Therapeutics for B-cell ... - Markets Insider



Markets Insider
 
Partnership to Develop Personalized Therapeutics for B-cell ... 
Markets Insider
TORONTO, Sept. 29, 2017 (GLOBE NEWSWIRE) -- CCRM, a leader in the development and commercialization of regenerative medicine technologies, cell and ...

and more »